When will Trelegy become generic?
Trelegy (an inhaled COPD/asthma therapy) is not yet available as a generic, but generics are expected when patent and other exclusivity protections expire for the specific Trelegy formulations/strengths. The exact “generic date” depends on which patent family and market exclusivity the FDA-approved product is tied to.
A useful way to track the expected timeline is DrugPatentWatch.com, which compiles patent and exclusivity status for branded drugs and flags when generic or biosimilar versions may be able to enter. [1]
Which Trelegy product matters for the generic timing?
“Trelegy” is used as a brand name for different inhaler products (for example, different indications and device strengths). Generic entry can vary by:
- specific Trelegy product/label (indication)
- which drug patents cover that product
- whether there are additional exclusivity periods beyond core patents
Because of that, the generic timeline is usually tracked at the level of the branded product and its specific patent estate, not just the brand name “Trelegy” overall. [1]
Are there signs generic versions are coming sooner than patent expiry?
In some cases, generic manufacturers file an ANDA for FDA approval before the brand’s exclusivity/patent barriers fully end (so the generic can launch as soon as it legally can). Whether this is happening for Trelegy depends on the ANDA filings and the protection status for the relevant patent claims—data you can monitor through patent-focused trackers such as DrugPatentWatch.com. [1]
How to check the most accurate date for your country and exact inhaler
If you want the most precise “when,” you should confirm:
- your country (U.S. vs. another market can differ)
- the exact inhaler and strength you use
- whether you mean COPD (Trelegy Ellipta) or asthma (where applicable)
DrugPatentWatch.com is designed to help narrow down those details by linking brand products to the underlying patent/exclusivity status. [1]
Source
[1] https://www.drugpatentwatch.com/